HBV

Hepatitis B virus (HBV) research compounds act on viral replication and on host steps of infection. HBV is a small enveloped DNA virus that copies its genome by reverse transcription of a pregenomic RNA inside the viral nucleocapsid. Nucleoside analogs such as telbivudine are phosphorylated in cells and then interfere with this reverse transcription step. Capsid assembly modulators work elsewhere in the cycle, and heteroaryldihydropyrimidines of the BAY41-4109 racemic type were shown to deplete nucleocapsids, while morphothiadin is a later capsid-directed compound. Virus entry depends on the bile acid transporter sodium taurocholate cotransporting polypeptide (NTCP), identified as the receptor for HBV. Catalpol is an iridoid glycoside listed here for reported activity in HBV cell models.

Items 126-150 of 162

  • Di-Val-L-dC
    Cat. No.
    A51012

    Di-Val-L-dC

    Di-Val-L-dC is a prodrug of L-deoxycytidine that targets hepatitis B virus (HBV) with specificity and selectivity. It exhibits potent antiviral activity against HBV, making it a valuable tool for research in viral infections and antiviral drug development. This compound provides insights into mechanisms of HBV replication and potential therapeutic interventions.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • HBV-IN-37
    Cat. No.
    A51015

    HBV-IN-37

    HBV-IN-37 is a selective inhibitor of Hepatitis B virus (HBV) with an EC50 value of 10 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researching therapeutic strategies against HBV infection. HBV-IN-37 is useful in elucidating the mechanisms of HBV replication and can serve as a lead compound in the development of antiviral agents targeting HBV.

    5 mg
    $20.00
    10 mg
    $35.00
    All 5 sizes
  • Yhhu6669
    Cat. No.
    A51016

    Yhhu6669

    Yhhu6669 is a potent inhibitor of Hepatitis B Virus (HBV), targeting HBV DNA replication. It functions by inducing the formation of DNA-free capsids, effectively reducing HBV levels. In preclinical studies using AAV/HBV-infected mouse models, Yhhu6669 demonstrated significant decreases in both HBV DNA and HBcAg. Additionally, it exhibits favorable pharmacokinetic properties, making it a valuable tool for research in HBV therapeutic development.

    Out of stock

    All 3 sizes
  • Tomligisiran
    Cat. No.
    A51017

    Tomligisiran

    Tomligisiran is a small interfering RNA (siRNA) designed to target hepatitis B virus (HBV) mRNAs, promoting their degradation and effectively inhibiting HBV replication. This reagent plays a significant role in research focused on antiviral strategies and therapeutic approaches for HBV infections. Its utility in silencing HBV-specific RNA makes it a valuable tool for studying the molecular mechanisms of viral replication and pathogenesis.

    Out of stock

    All 3 sizes
  • HBV-IN-7
    Cat. No.
    A51018

    HBV-IN-7

    HBV-IN-7 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 of 7 nM. This compound effectively interferes with viral replication, making it a valuable tool for researching HBV pathogenesis and therapeutic interventions. Its strong antiviral activity supports applications in the development of treatments for chronic hepatitis B infections.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • HBV-IN-8
    Cat. No.
    A51019

    HBV-IN-8

    HBV-IN-8 is a potent inhibitor of hepatitis B virus (HBV) with an effective concentration (EC50) of 287.9 nM. This compound offers significant antiviral activity, making it a valuable tool for research applications focused on HBV infection and treatment mechanisms. HBV-IN-8 is suitable for investigations into the efficacy of antiviral agents in the pursuit of therapeutic strategies against HBV-related diseases.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (5S,8R)-HBV-IN-10
    Cat. No.
    A51022

    (5S,8R)-HBV-IN-10

    (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 and functions as a hepatitis B surface antigen (HBsAg) inhibitor, displaying an EC50 range of 0.001 μM to 0.05 μM. This compound is designed for investigating antiviral strategies against hepatitis B virus infections. Its capability to inhibit HBsAg makes it a valuable tool in research aimed at developing therapeutic interventions for hepatitis B-related diseases.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • CAB7-3
    Cat. No.
    A51025

    CAB7-3

    CAB7-3 is an orally active capsid assembly modulator targeting Hepatitis B Virus (HBV), exhibiting potent antiviral activity. It demonstrates significant efficacy with EC50 values of 70 nM in HepDES19 cells, 1 nM in HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication in vivo. This compound is valuable for research aimed at understanding and treating HBV infections.

    Out of stock

    All 3 sizes
  • GS-8873
    Cat. No.
    A51027

    GS-8873

    Synonyms: HBV-IN-19

    GS-8873 is an orally active inhibitor targeting hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 of 4 nM. This compound demonstrates favorable pharmacokinetic properties in rat models and shows metabolic stability in human hepatocytes. While GS-8873 effectively suppresses HBV, it has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a subject of interest for further research into its biological effects and therapeutic potential.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • HBV-IN-30
    Cat. No.
    A51028

    HBV-IN-30

    HBV-IN-30 is a selective inhibitor of covalently closed circular DNA (cccDNA), a critical component in the life cycle of hepatitis B virus (HBV). By targeting cccDNA, HBV-IN-30 disrupts viral RNA transcription and subsequent viral DNA synthesis, thereby impeding HBV replication. This reagent is valuable for research applications focused on understanding HBV infection and developing therapeutic strategies against chronic hepatitis B.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • (Rac)-AB-423
    Cat. No.
    A51029

    (Rac)-AB-423

    Synonyms: DVR-23

    (Rac)-AB-423 is a novel inhibitor targeting hepatitis B virus (HBV) with demonstrated antiviral activity. This compound has shown no induction of CYP1A2, CYP3A4, or CYP2B6 enzymes at elevated concentrations, indicating a favorable safety profile. Additionally, (Rac)-AB-423 exhibits advantageous pharmacokinetic characteristics, including high oral bioavailability and systemic exposure. In preclinical studies using a hydrodynamic injection HBV mouse model, (Rac)-AB-423 achieved a viral load reduction exceeding 2 log, highlighting its potential for therapeutic applications in HBV management.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Schisanwilsonin C
    Cat. No.
    A51031

    Schisanwilsonin C

    Synonyms: Arisanschinin K

    Schisanwilsonin C is an anti-HBV agent that demonstrates significant activity against hepatitis B virus. This compound has been studied for its potential in antiviral research, offering insights into therapeutic strategies for managing HBV infections. Its efficacy in targeting viral replication makes it a valuable tool for further investigations in hepatitis B research.

    1 mg
    $265.00
    5 mg
    $345.00
    All 2 sizes
  • (1R,3S,4R)-ent-Entecavir
    Cat. No.
    A51032

    (1R,3S,4R)-ent-Entecavir

    Synonyms: (1R,3S,4R)-ent-BMS200475; (1R,3S,4R)-ent-SQ34676

    (1R,3S,4R)-ent-Entecavir is an inhibitor of hepatitis B virus (HBV) replication, primarily targeting viral DNA polymerase. This compound is valuable for research applications focused on HBV control and offers potential for the development of PROTACs aimed at degrading viral DNA polymerase. Its structural analog attributes enhance its utility in studying antiviral mechanisms and therapeutic strategies against HBV infection.

    1 mg
    $675.00
    10 mg
    $1,370.00
    All 5 sizes
  • HBV-IN-32
    Cat. No.
    A51033

    HBV-IN-32

    HBV-IN-32 is a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrating significant antiviral effects against Hepatitis B virus (HBV). With an IC50 value of 0.14 µM for Hepatitis B surface antigen (HBsAg), HBV-IN-32 effectively suppresses HBV replication. It also exhibits inhibitory effects on cell proliferation, making it a valuable tool for research on HBV-related diseases and potential therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-20
    Cat. No.
    A51034

    HBV-IN-20

    HBV-IN-20 is a potent oral active inhibitor of Hepatitis B Virus (HBV), functioning primarily as a type II core protein assembly modulator (CpAM). With an EC50 of 0.46 µM, HBV-IN-20 disrupts the assembly of HBV core particles, thereby impeding viral replication. This compound is particularly valuable for research applications focused on antiviral therapy and understanding HBV biology.

    Out of stock

    All 3 sizes
  • AB-161
    Cat. No.
    A51035

    AB-161

    AB-161 is an orally active HBV RNA destabilizer and a selective inhibitor of poly(A) polymerase domain-containing proteins 5 and 7 (PAPD5/7), primarily targeting hepatic tissues. This compound is effective in treating Hepatitis B Virus (HBV) infections by significantly reducing the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 is a valuable tool for research applications focused on understanding and addressing HBV infection.

    Out of stock

    All 3 sizes
  • LP10
    Cat. No.
    A51036

    LP10

    LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • DVR-01
    Cat. No.
    A51038

    DVR-01

    DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions.

    1 mg
    $255.00
    All 1 sizes
  • Lagociclovir valactate
    Cat. No.
    A51040

    Lagociclovir valactate

    Lagociclovir valactate is a prodrug of Lagociclovir, designed for oral administration as an anti-hepatitis B virus (HBV) agent. It exhibits potent antiviral activity against HBV, making it valuable for research related to viral infections and hepatitis B treatment strategies. This compound aids in the exploration of effective therapeutic options in the management of HBV-related diseases.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • KKJ00626
    Cat. No.
    A51043

    KKJ00626

    KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside
    Cat. No.
    A51044

    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside

    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is a compound targeting hepatitis B virus (HBV) through the inhibition of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion. This agent has demonstrated effective antiviral activity in the Hep G2.2.15 cell line, with IC50 values of 1.67 mM for HBsAg and greater than 2.15 mM for HBeAg. It is beneficial for research focusing on HBV infection and therapeutic development against hepatitis B.

    1 mg
    $300.00
    5 mg
    $770.00
    All 3 sizes
  • HBV/HDV-IN-5
    Cat. No.
    A51045

    HBV/HDV-IN-5

    HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections.

    Out of stock

    All 3 sizes
  • Periglaucine A
    Cat. No.
    A51048

    Periglaucine A

    Periglaucine A is a hasubanane-type alkaloid that targets anti-HBV and anti-HIV-1 activity. It effectively inhibits the secretion of HBV surface antigen (HBsAg) in Hep G2.2.15 cells, demonstrating its potential as a therapeutic agent against hepatitis B virus. Additionally, Periglaucine A exhibits anti-HIV-1 efficacy in C8166 cells, with an EC50 value of 204 μM, making it a valuable compound for research in viral infections.

    5 mg
    $540.00
    All 1 sizes
  • Acutumidine
    Cat. No.
    A51051

    Acutumidine

    Acutumidine is an alkaloid known for its anti-HBV activity, derived from the plant Hypserpa nitida Miers. This compound effectively inhibits the production of hepatitis B surface antigen (HBsAg) in Hep G2.2.15 cells that are stably transfected with the HBV genome, demonstrating an IC50 value of 2.023 mM. Acutumidine shows potential for research applications in the study of hepatitis B virus infection and its pathways.

    5 mg
    $1,075.00
    All 1 sizes
  • ZINC20451377
    Cat. No.
    A51052

    ZINC20451377

    ZINC20451377 is a small molecule that targets the hepatitis B surface antigen (HBsAg) and demonstrates significant inhibitory activity against both wild-type hepatitis B virus and tenofovir-resistant variants. This compound is valuable for research applications focused on hepatitis B virus infection and developing novel therapeutics for hepatitis B. Its ability to target multiple strains makes it an important tool in the study of antiviral resistance and vaccine development.

    Out of stock

    All 3 sizes

Items 126-150 of 162

Added to your cart

View Cart Checkout

    Loading...